Current Report Filing (8-k)
September 19 2017 - 6:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
September 13, 2017
Ekso Bionics Holdings, Inc.
(Exact
Name of Registrant as specified in its charter)
Nevada
|
001-37854
|
99-0367049
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
1414 Harbour Way South, Suite 1201
Richmond, California 94804
(Address of principal executive offices,
including zip code)
(510) 984-1761
(Registrant’s telephone number, including
area code)
Not Applicable
(Registrant’s name or former address,
if change since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (
see
General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
x
|
Item 3.02
|
Unregistered Sales of Equity Securities.
|
On September 13, 2017, Ekso Bionics Holdings,
Inc. (the “Company”) entered into an amendment to the information agent agreement between the Company and Katalyst
Securities LLC (“Katalyst”) dated August 11, 2017 (the “Information Agent Agreement”). Pursuant to the
amendment, the Company agreed to issue to Katalyst, or its designee, warrants to purchase an aggregate of 200,000 shares of the
Company’s common stock, par value $0.001 per share (the “Common Stock”), at an exercise price of $1.50 per share
(the “Warrants”). The Warrants will be exercisable immediately and will expire three years from the date of issuance.
The Warrants were issued to Katalyst as compensation for its services as information agent in connection with the Company’s
recently completed rights offering in lieu of the $200,000 in cash compensation that would otherwise have been payable to Katalyst
pursuant to the Information Agent Agreement.
The Company issued the Warrants and will
issue the shares of Common Stock issuable upon exercise of the Warrants in reliance upon the exemption from registration under
Section 4(a)(2) of the Securities Act.
The foregoing description of the Warrants
does not purport to be complete and is qualified in its entirety by reference to the form of Warrant attached hereto as Exhibit
4.1, which is incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
EKSO BIONICS HOLDINGS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Maximilian Scheder-Bieschin
|
|
|
Name:
Title:
|
Maximilian Scheder-Bieschin
Chief Financial Officer
|
Dated: September 19, 2017
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024